Journal article icon

Journal article

Advances in systemic delivery of anti-cancer agents for the treatment of metastatic cancer

Abstract:

Introduction: The successful treatment of metastatic cancer is refractory to strategies employed to treat confined, primary lesions, such as surgical resection and radiation therapy, and thus must be addressed by systemic delivery of anti-cancer agents. Conventional systemically administered chemotherapeutics are often ineffective and come with severe dose-limiting toxicities.

Areas covered: This review focuses on the recent developments in systemic therapy for metastatic cancer. Firstly, the strategies employed to improve the efficacy of conventional chemotherapeutics by ‘passively’ and ‘actively’ targeting them to tumors are discussed. Secondly, recent advances in the use of biologics to better target cancer and to instigate anti-tumor immunity are reviewed. Under the label of ‘biologics’, antibody-therapies, T cell engaging therapies, oncolytic virotherapies and cell-based therapies are examined and evaluated.

Expert opinion: Improving specificity of action, and engaging the immune system appear to be key goals in the development of novel or reformulated anti-cancer agents for the treatment of metastatic cancer. One of the largest areas of opportunity in this field will be the identification of robust predictive biomarkers for use in conjunction with these agents. Treatment regimens that combine an agent to elicit an immune response (such as an oncolytic virus), and an agent to potentiate/mediate that immune response (such as immune checkpoint inhibitors) are predicted to be more effective than treatment with either agent alone.

Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1517/17425247.2016.1167036

Authors


More by this author
Institution:
University of Oxford
Division:
MPLS
Department:
Engineering Science
Sub department:
Institute of Biomedical Engineering
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MPLS
Department:
Engineering Science
Sub department:
Institute of Biomedical Engineering
Role:
Author
ORCID:
0000-0001-8792-7818
More by this author
Institution:
University of Oxford
Division:
MPLS
Department:
Engineering Science
Sub department:
Institute of Biomedical Engineering
Role:
Author
ORCID:
0000-0003-4508-4802


More from this funder
Funder identifier:
https://ror.org/0439y7842
Grant:
EP/L024012


Publisher:
Taylor and Francis
Journal:
Expert Opinion on Drug Delivery More from this journal
Volume:
13
Issue:
7
Pages:
999-1013
Publication date:
2016-04-15
Acceptance date:
2016-03-14
DOI:
EISSN:
1744-7593
ISSN:
1742-5247


Language:
English
Keywords:
Pubs id:
pubs:618436
UUID:
uuid:aabbaf67-8334-47ce-aeff-66100397cafc
Local pid:
pubs:618436
Source identifiers:
618436
Deposit date:
2016-06-24

Terms of use



Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP